IL17A and rheumatoid arthritis: One example is the lack of therapeutic efficacy of interleukin (IL-) 17 inhibitors in RA patients (16, 17), although suppression of IL-17 signaling had been shown to reduce joint inflammation as well as cartilage and bone destruction in mice (18).